Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

SPARC - Screening for lungekræft med trombocytter via en AI-drevet RNA-baseret klassifikator (SPARC)

25. september 2026 opdateret af: University of Utah

SPARC - Screening for Lungekræft med Blodplader via en AI-drevet RNA-baseret Klassifikator

The purpose of this study is to test whether combining a unique analytical approach with changes in platelet RNA expression accurately diagnoses lung cancer. Using retrospective platelet transcriptomic data from 522 patients with non-small cell lung cancer (NSCLC, the most common type of lung cancer), an approach that appears to accurately classify lung cancer has been developed.

The study will build upon these retrospective analyses to prospectively recruit patients with newly diagnosed lung cancer, obtain platelet RNA samples from whole blood, and perform validation analyses. This research will also test whether this approach accurately distinguishes benign from malignant lung nodules.

Studieoversigt

Status

Rekruttering

Betingelser

Undersøgelsestype

Observationel

Tilmelding (Anslået)

240

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84112
        • Rekruttering
        • University of Utah
        • Kontakt:
        • Ledende efterforsker:
          • Shiven Patel, MD/MBA
      • Salt Lake City, Utah, Forenede Stater, 84148-0001
        • Rekruttering
        • Veterans Affairs SLC Health Care System (VAMC)
        • Kontakt:
        • Ledende efterforsker:
          • Emily Beck, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

21 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

The population from which the cohorts will be selected will be from the Huntsman Cancer Institute University of Utah (HCI/UU) and the George E. Wahlen Veterans Affairs Medical Center (VAMC) in Salt Lake City, Utah.

Beskrivelse

Study Population 1: Treatment-Naïve Patients with a Lung Nodule or Lung Cancer

Inclusion Criteria:

  • Aged 21 years or older
  • Meeting at least one of the following two criteria:
  • Diagnosed with any stage or type of lung cancer
  • Having at least one lung nodule identified on imaging (e.g., low dose computed tomography [LDCT] or other diagnostic chest imaging) that was completed within 180 days prior to enrollment, and where there is planned or recommended biopsy, surgical resection, radiation therapy, systemic therapy, or other invasive diagnostic or therapeutic procedure to further evaluate the nodule(s) in the next six months based on the clinical judgment of the patient's provider(s)

Exclusion Criteria:

  • Other diagnosis of, or treatment for, any cancer within the last 6 months except for non-melanoma skin cancer, carcinoma in situ of the cervix, or low-grade prostate cancer (defined as Gleason score ≤ 6) treated locally
  • A history of lung cancer or metastatic cancer to the lungs from an extrathoracic primary site with definitive treatment (surgical, medical, or radiotherapy) within the past 2 years
  • Currently receiving any systemic therapy (chemotherapy, immunotherapy, and/or targeted therapy) or radiation therapy for lung cancer
  • Already undergone surgical resection of the lung cancer in part or in whole
  • Have undergone invasive diagnostic or therapeutic procedures (e.g., biopsy, surgery) related to the lung nodule within the past 3 months
  • Unable to provide blood sample

Study Population 2: Control Subjects

Inclusion Criteria:

  • Aged 21 years or older

Exclusion Criteria:

  • Any active malignancy or diagnosis of cancer within the last 6 months except for non-melanoma skin cancer, carcinoma in situ of the cervix, or low-grade prostate cancer (defined as Gleason score ≤ 6) treated locally
  • Treatment for any cancer within the last 6 months except for non-melanoma skin cancer, carcinoma in situ of the cervix, or low-grade prostate cancer (defined as Gleason score ≤ 6) treated locally
  • Hospitalization or surgery (other than minor surgery such as mole removal) within the last 8 weeks
  • Renal failure (defined as eGFR < 60 mL/min/1.73m² or on dialysis)
  • Liver failure (defined as having hepatic encephalopathy of any degree, OR moderately severe coagulopathy defined as INR ≥ 1.5, OR known cirrhosis, OR ALT of ≥ 10X ULN, OR total bilirubin of ≥ 3.0 mg/dL, OR diagnosis of liver failure)
  • Decompensated or end-stage heart failure (defined as ACC/AHA Stage C or Stage D heart failure)
  • Venous thrombosis, myocardial infarction, or stroke within the last 8 weeks
  • Currently pregnant or have been pregnant within the last 12 weeks
  • Any blood product transfusion within the last 8 weeks
  • Personal history of lung cancer at any time
  • Unable to provide blood sample

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: CASE_CONTROL
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Cohort 1: Lung Cancer

Cohort 1 will enroll 90 participants with Lung Cancer (30 patients with Stage I/II and 60 participants with Stage III/IV).

Following informed consent and during the same visit (study visit 1), up to 20mL (the maximum blood volume collected) of whole blood will be collected by peripheral venipuncture by a site phlebotomist into sterile, 4mL EDTA-containing venipuncture tubes.

Up to 20mL (the maximum blood volume collected) of whole blood will be collected by peripheral venipuncture by a site phlebotomist into sterile, 4mL EDTA-containing venipuncture tubes. The minimum whole blood collected will be 4mL.

Cohort 2: Lung Nodule

Cohort 1 will enroll 120 participants with Lung Nodules (72 patients with Benign Nodules and 48 participants with Malignant Nodules).

Following informed consent and during the same visit (study visit 1), up to 20mL (the maximum blood volume collected) of whole blood will be collected by peripheral venipuncture by a site phlebotomist into sterile, 4mL EDTA-containing venipuncture tubes.

Up to 20mL (the maximum blood volume collected) of whole blood will be collected by peripheral venipuncture by a site phlebotomist into sterile, 4mL EDTA-containing venipuncture tubes. The minimum whole blood collected will be 4mL.

Cohort 3: Control Participants without Cancer or Nodule

Cohort 3 will enroll 30 participants without Lunch Cancer or lunch Nodules.

Following informed consent and during the same visit (study visit 1), up to 20mL (the maximum blood volume collected) of whole blood will be collected by peripheral venipuncture by a site phlebotomist into sterile, 4mL EDTA-containing venipuncture tubes.

Up to 20mL (the maximum blood volume collected) of whole blood will be collected by peripheral venipuncture by a site phlebotomist into sterile, 4mL EDTA-containing venipuncture tubes. The minimum whole blood collected will be 4mL.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Sensitivity
Tidsramme: up to one day after study enrollment

Sensitivity of the assay in detecting lung cancer

up to one day after study enrollment
Specificity
Tidsramme: up to one day after study enrollment

Specificity of the assay in detecting lung cancer.

up to one day after study enrollment
Positive predictive value (PPV)
Tidsramme: up to one day after study enrollment

Positive predictive value (PPV) in distinguishing benign vs. malignant lung nodules.

up to one day after study enrollment
Negative Predictive Value (NPV)
Tidsramme: up to one day after study enrollment

Negative predictive value (NPV) in distinguishing benign vs. malignant lung nodules.

up to one day after study enrollment

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Performance Across Lung Cancer Stage
Tidsramme: up to one day after study enrollment

Performance of the assay across lung cancer stage (stage I-IV).

up to one day after study enrollment
Performance Across Lung Cancer Histologic Subtypes
Tidsramme: up to one day after study enrollment

Performance of assay across lung cancer histologic subtypes (e.g., adenocarcinoma, squamous, small cell).

up to one day after study enrollment
Validation Completion
Tidsramme: up to one day after study enrollment

Technical and analytical validation completion.

up to one day after study enrollment

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Shiven Patel, MD/MBA, University of Utah

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

8. september 2026

Primær færdiggørelse (Anslået)

1. juni 2028

Studieafslutning (Anslået)

1. juni 2028

Datoer for studieregistrering

Først indsendt

3. marts 2026

Først indsendt, der opfyldte QC-kriterier

3. marts 2026

Først opslået (Faktiske)

10. marts 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

28. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

25. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 193163
  • LC240423 (Andet bevillings-/finansieringsnummer: US DEPARTMENT OF DEFENSE)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner